Key insights
- City Therapeutics Inc. (CTY) experienced a strong market debut, surging 28% after an upsized $200 million IPO. The biotechnology firm's shares opened at $23.00, significantly above the $18.00 IPO price, reflecting robust institutional demand for RNA interference developers. The capital raised will fund the advancement of its proprietary RNAi platform and therapeutic pipelines, addressing conditions like thromboembolic disorders and Stargardt disease.
City Therapeutics Inc (NASDAQ: CTY) made a strong Nasdaq debut on Friday, surging 28% after raising $200 million in an upsized initial public offering. The Cambridge, Massachusetts-based biotechnology firm sold 11.11 million shares at $18.00 each, the midpoint of its expected target range, after expanding the offering from an initial plan of 9.72 million shares.
Trading opened at $23.00 under the ticker symbol "CTY," pushing the company’s valuation to approximately $1.19 billion based on total outstanding shares. The offering, backed by prominent healthcare investors Arch Venture Partners and Fidelity Management & Research, underscored robust institutional demand for early-stage RNA interference developers.
The clinical-stage biotech granted underwriters a 30-day option to buy up to an additional 1.67 million shares at the IPO price. Proceeds are expected to fund the advancement of City’s proprietary RNAi platform and its lead therapeutic pipelines, led by joint book-running managers Goldman Sachs & Co. LLC, Jefferies, Stifel, and Oppenheimer & Co.
City Therapeutics is leveraging its specialized trigger engineering platform to address key functional limitations present in conventional RNAi approaches. The company’s pipeline includes CITY-FXI for thromboembolic conditions, CITY-RBP4 targeting Stargardt disease, and CITY-TFR2 aimed at chronic disease-associated anemia.
The debut reflects growing investor appetite for platform-based genetic medicine developers capable of tissue-selective drug delivery. Against that backdrop, the capital influx provides City Therapeutics with significant runway to advance its clinical programs toward pivotal milestone readouts.
Original Article